4 Jun 2021
ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
14 Mar 2023HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside ChinaRead more 13 Mar 2023HUTCHMED Confirms No Assets Held at Silicon Valley BankRead more 28 Feb 2023HUTCHMED Reports 2022 Full Year Results and Provides Business UpdatesRead more
27 Feb 2023HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in ChinaRead more 31 Jan 2023HUTCHMED to Announce 2022 Final ResultsRead more 23 Jan 2023HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside ChinaRead more 18 Jan 2023HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in ChinaRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
